BG102412A - Производни на 5-фенил-3-/пиперидин-4-ил/-1,3,4-оксадиазол- 2-/3н/-он полезни като лиганди на рецепторите 5-нт4 или н3 - Google Patents

Производни на 5-фенил-3-/пиперидин-4-ил/-1,3,4-оксадиазол- 2-/3н/-он полезни като лиганди на рецепторите 5-нт4 или н3

Info

Publication number
BG102412A
BG102412A BG102412A BG10241298A BG102412A BG 102412 A BG102412 A BG 102412A BG 102412 A BG102412 A BG 102412A BG 10241298 A BG10241298 A BG 10241298A BG 102412 A BG102412 A BG 102412A
Authority
BG
Bulgaria
Prior art keywords
group
piperidin
receptors
phenyl
alkyl
Prior art date
Application number
BG102412A
Other languages
English (en)
Other versions
BG63463B1 (bg
Inventor
Samir Jegham
Alistair Lochead
Frederic Galli
Alain Nedelec
Axelle Solignac
Cruz Laurence De
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9513252A external-priority patent/FR2741069B1/fr
Priority claimed from FR9513253A external-priority patent/FR2741070B1/fr
Priority claimed from FR9602663A external-priority patent/FR2745574B1/fr
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of BG102412A publication Critical patent/BG102412A/bg
Publication of BG63463B1 publication Critical patent/BG63463B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Съединенията са приложими за предотвратяване и лечение на заболявания, при които се включват рецепторите 5-НТ4 и/или Н3, по-специално в централната нервна система, стомашно-чревната система, органитеот долните пикочни пътища или сърдечно-съдовата система. Те имат обща формула, в която R1 е група (С1-С4)-алкил или (С3-С7)-циклоалкилметил, Х1 e водороден или халогенeнатом или (С1-С4)-алкоксигрупа или OR1 и Х1 заедно са група с формула -ОСН20-, -0(СН2)2-, -0(СН2)3-, -0(СН2)20 или -0(СН2)30-, Х2 е водороден атом или аминогрупа, Х3 водороден или халогенен атом и R2 е или водороден атом, или (С1-С6)-алкилова група, в даден случай заместена, или фенил-(С1-С4)-алкилова група, в даден случай заместена във фениловия пръстен, или фенил-(С2-С3)-алкенилова група, или фенокси-(С2-С4)-алкилова група, или цикло-(С3-С7)-алкилметилова група, или 2,3-дихидро-1Н-инден-1-илова или 2,3-дихидро-1Н-инден-2-илова група, или група с обща формула -(СН2)nCO-Z, в която n има стойност от 1 до 6 и Z е пиперидин-1-илова или 4-(диметиламино)пиперидин-1-илова група.
BG102412A 1995-11-09 1998-04-28 Производни на 5-фенил-3-/пиперидин-4-ил/-1,3,4-оксадиазол- 2-/3н/-он полезни като лиганди на рецепторите 5-нт4 или н3 BG63463B1 (bg)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9513252A FR2741069B1 (fr) 1995-11-09 1995-11-09 Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
FR9513253A FR2741070B1 (fr) 1995-11-09 1995-11-09 Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
FR9602663A FR2745574B1 (fr) 1996-03-04 1996-03-04 Derives de 5-phenyl-3-(piperidin-4-yl)-1, 3, 4-oxadiazol-2 (3h)-one, leur preparation et leur application en therapeutique
PCT/FR1996/001730 WO1997017345A1 (fr) 1995-11-09 1996-11-05 Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one, utiles comme ligands des recepteurs 5-ht4 ou h¿3?

Publications (2)

Publication Number Publication Date
BG102412A true BG102412A (bg) 1999-08-31
BG63463B1 BG63463B1 (bg) 2002-02-28

Family

ID=27253120

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102412A BG63463B1 (bg) 1995-11-09 1998-04-28 Производни на 5-фенил-3-/пиперидин-4-ил/-1,3,4-оксадиазол- 2-/3н/-он полезни като лиганди на рецепторите 5-нт4 или н3

Country Status (30)

Country Link
US (1) US5929089A (bg)
EP (1) EP0863897B1 (bg)
JP (1) JP4263240B2 (bg)
CN (1) CN1077891C (bg)
AR (1) AR004708A1 (bg)
AT (1) ATE181328T1 (bg)
AU (1) AU707325B2 (bg)
BG (1) BG63463B1 (bg)
BR (1) BR9611311A (bg)
CA (1) CA2236357C (bg)
CO (1) CO4770968A1 (bg)
CZ (1) CZ287268B6 (bg)
DE (1) DE69602970T2 (bg)
EE (1) EE03487B1 (bg)
ES (1) ES2135934T3 (bg)
GR (1) GR3030823T3 (bg)
HK (1) HK1016165A1 (bg)
HU (1) HUP0001168A3 (bg)
IL (1) IL124364A (bg)
MX (1) MX9803696A (bg)
NO (1) NO309606B1 (bg)
NZ (1) NZ321626A (bg)
PL (1) PL186204B1 (bg)
RU (1) RU2167160C2 (bg)
SI (1) SI0863897T1 (bg)
SK (1) SK282335B6 (bg)
TR (1) TR199800827T2 (bg)
TW (1) TW371303B (bg)
UA (1) UA50748C2 (bg)
WO (1) WO1997017345A1 (bg)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW467902B (en) 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
FR2762316B1 (fr) * 1997-04-18 1999-12-17 Sanofi Synthelabo Derives de 5-aryl-3-(8-azabicyclo[3.2.1] octan-3-yl)-1,3,4- oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
FR2763068B1 (fr) * 1997-05-06 1999-06-04 Synthelabo Derives de 3-(pyrrolidin-3-yl)-1,3,4-oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
WO1998050383A1 (fr) * 1997-05-06 1998-11-12 Sanofi-Synthelabo Derives de 5-phenyl-1,3,4-oxadiazol-2(3h)-one et leur utilisation comme ligands 5-ht4
GB9715816D0 (en) * 1997-07-25 1997-10-01 Black James Foundation Histamine H receptor ligands
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
ATE310566T1 (de) 1998-09-18 2005-12-15 Alcon Mfg Ltd 5ht2-agoniste zur behandlung des glaukoms
AU5259100A (en) * 1999-04-28 2000-11-10 Respiratorius Ab Medicament
EP1185263A2 (en) * 1999-06-15 2002-03-13 Respiratorius AB Receptor agonists and antagonists
ES2260276T3 (es) 2000-08-08 2006-11-01 Ortho-Mcneil Pharmaceutical, Inc. Ariloxialquilaminas no imidazolicas como ligandos del receptor h3.
KR100852362B1 (ko) 2000-08-08 2008-08-14 오르토-맥네일 파마슈티칼, 인코퍼레이티드 비-이미다졸 아릴옥시피페리딘
AU2001281119A1 (en) 2000-08-08 2002-02-18 Ortho-Mcneil Pharmaceutical, Inc. Bicyclic compounds as h3 receptor ligands
US7208497B2 (en) 2001-07-02 2007-04-24 Novo Nordisk A/S Substituted piperazines and diazepanes
DE60234453D1 (de) 2001-07-02 2009-12-31 High Point Pharmaceuticals Llc Substituierte piperazin- und diazepanderivate zur verwendung als histamin h3 rezeptormodulatoren
US20030186963A1 (en) 2001-09-14 2003-10-02 Dorwald Florencio Zaragoza Substituted piperidines
ATE450508T1 (de) * 2001-09-14 2009-12-15 High Point Pharmaceuticals Llc Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren
ATE479655T1 (de) 2001-09-14 2010-09-15 High Point Pharmaceuticals Llc Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
US6673829B2 (en) 2001-09-14 2004-01-06 Novo Nordisk A/S Aminoazetidine,-pyrrolidine and -piperidine derivatives
US7064135B2 (en) 2001-10-12 2006-06-20 Novo Nordisk Inc. Substituted piperidines
WO2003031432A1 (en) 2001-10-12 2003-04-17 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
JP2005511764A (ja) 2001-12-14 2005-04-28 アルコン，インコーポレイテッド 緑内障の処置のためのアミノアルキルベンゾフラン−５−オール化合物
US20030236259A1 (en) * 2002-02-05 2003-12-25 Rolf Hohlweg Novel aryl- and heteroarylpiperazines
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
US7332508B2 (en) 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
WO2005123718A2 (en) 2004-06-15 2005-12-29 Pfizer Japan Inc. Benzimidazolone carboxylic acid derivatives
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
EP2386554A1 (en) * 2005-07-04 2011-11-16 High Point Pharmaceuticals, LLC Compounds active at the histamine H3 receptor
ATE538116T1 (de) * 2006-05-29 2012-01-15 High Point Pharmaceuticals Llc 3-(1,3-benyodioxol-5-yl)-6- (4- cyclopropylpiperazin-1-yl)-pyridazin, dessen salze und solvate und dessen verwendung als histamin-h3-rezeptorantagonist
EP2014656A3 (en) * 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
EA022374B1 (ru) * 2011-09-19 2015-12-30 Сувен Лайф Сайенсиз Лимитед Гетероарильные соединения в качестве лигандов 5-htрецептора

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003725A1 (en) * 1991-08-20 1993-03-04 Smithkline Beecham Plc 5-ht4 receptor antagonists
DK0604494T3 (da) * 1991-09-12 1999-11-29 Smithkline Beecham Plc 5-HT4-receptorantagonister
EP0625149A1 (en) * 1992-02-06 1994-11-23 Smithkline Beecham Plc Benzopyran, benzothiopyran and benzofuran derivatives as 5-ht4 antagonists
GB9219163D0 (en) * 1992-09-10 1992-10-28 Smithkline Beecham Plc Pharmaceuticals
JPH06157518A (ja) * 1992-11-27 1994-06-03 Yamanouchi Pharmaceut Co Ltd 新規なオキサジアゾール誘導体又はその塩

Also Published As

Publication number Publication date
DE69602970T2 (de) 2000-01-20
WO1997017345A1 (fr) 1997-05-15
EE9800155A (et) 1998-12-15
SI0863897T1 (en) 1999-10-31
PL186204B1 (pl) 2003-11-28
EP0863897A1 (fr) 1998-09-16
SK59998A3 (en) 1998-11-04
DE69602970D1 (de) 1999-07-22
AR004708A1 (es) 1999-03-10
UA50748C2 (uk) 2002-11-15
CA2236357C (en) 2006-10-17
ATE181328T1 (de) 1999-07-15
NO982092L (no) 1998-06-29
CO4770968A1 (es) 1999-04-30
CN1202169A (zh) 1998-12-16
EE03487B1 (et) 2001-08-15
CN1077891C (zh) 2002-01-16
NO309606B1 (no) 2001-02-26
AU7500196A (en) 1997-05-29
JP2000500125A (ja) 2000-01-11
TW371303B (en) 1999-10-01
GR3030823T3 (en) 1999-11-30
CZ142198A3 (cs) 1998-08-12
BG63463B1 (bg) 2002-02-28
MX9803696A (es) 1998-09-30
PL326671A1 (en) 1998-10-12
CA2236357A1 (en) 1997-05-15
NO982092D0 (no) 1998-05-07
HUP0001168A2 (hu) 2001-04-28
BR9611311A (pt) 1999-06-29
US5929089A (en) 1999-07-27
EP0863897B1 (fr) 1999-06-16
IL124364A (en) 2001-08-08
ES2135934T3 (es) 1999-11-01
RU2167160C2 (ru) 2001-05-20
AU707325B2 (en) 1999-07-08
CZ287268B6 (en) 2000-10-11
SK282335B6 (sk) 2002-01-07
JP4263240B2 (ja) 2009-05-13
NZ321626A (en) 1998-10-28
HUP0001168A3 (en) 2001-07-30
HK1016165A1 (en) 1999-10-29
IL124364A0 (en) 1998-12-06
TR199800827T2 (xx) 1999-02-22

Similar Documents

Publication Publication Date Title
BG102412A (bg) Производни на 5-фенил-3-/пиперидин-4-ил/-1,3,4-оксадиазол- 2-/3н/-он полезни като лиганди на рецепторите 5-нт4 или н3
DE59410116D1 (de) Kombinationsprodukt zur kontrazeption enthaltend progesteronantagonisten und gestagenen
BG104813A (bg) Заместени индолинони с инхибиращ ефект върху кинази и комплекси циклин/cdk
GEP20033094B (en) Steroid Sulphatase Inhibitors
TW325458B (en) Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer
CA2304770A1 (en) A use of steroidal saponins for the prophylaxis or treatment of dementia, and novel steroidal saponin compounds
HU9302965D0 (en) Substituted benzyl amino-quinuclidine derivatives
AP9100310A0 (en) Tnf inhibitors
ATE293979T1 (de) Pharmazeutische zusammensetzungen enthaltend syntethisch natürliche progesteron und estradiol und verfahren zur herstellung derselben
IL139090A0 (en) Compounds with growth hormone releasing properties
HK1018701A1 (en) Benzopyran derivatives having leukotriene-antagonistic action.
HU9902668D0 (en) Compounds with growth hormone releasing properties
TR199900363T2 (xx) NK1 ve NK2 antagonistleri olarak asilaminoalkenilen-amid t�revleri.
TW324009B (en) Pyrazole condensation ring derivative, its production process and its use as androgen inhibitor
PL327060A1 (en) Application of 2-ethylhexyl alpha-cyano-beta,beta-diphemylacrylate to improve stability of cosmetic compositions containing p-methylbenzylibene camphor in combination with a derivative of dibenzoyl methane
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
BR9809804A (pt) Piperazinas substituìdas com arila úteis no tratamento de hiperplasia benigna da próstata
HUT61971A (en) Process for producing new derivative of beta-phenylisoserine
TW328957B (en) Substituted benzothienylpiperazines, their use as medicaments, and processes for their preparation
MD940297A (ro) Noi derivaţi tienotiazinici, procedeu de obţinere a lor şi remediu farmaceutic
DK1100824T3 (da) Forbindelser med væksthormonfrigivende egenskaber
MY101961A (en) 4-nitrogen substituted isoquinolinol compounds having cardiotonic, phosphodiesterease fraction iii inhibiting properties and/or renal vasodilating properties
NO952949L (no) Forlöpere av anti-inflamatoriske 3-acyl-2-oksindol-1-karboksamider
MX9700712A (es) Derivados de estreptogramina, su preparacion y las composiciones farmaceuticas que los contienen.
DE60023034D1 (en) Cd45 hemmer